Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; TRND 5: Pharmacology Studies, Animal Model Development & Related Services for Drug Development.

Date: November 15, 2023.

Time: 1:00 p.m. to 4:30 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd., Room 1073, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: M. Lourdes Ponce, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd., Room 1073, Bethesda, MD 20892, 301–435–0810, lourdes.ponce@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: September 26, 2023.

Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

FR Doc. 2023–21590 Filed 9–29–23; 8:45 am

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Advancing Translational Sciences; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; TRND 5: Pharmacology Studies, Animal Model Development & Related Services for Drug Development.

Date: November 15, 2023.

Time: 1:00 p.m. to 4:30 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd., Room 1073, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: M. Lourdes Ponce, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd., Room 1073, Bethesda, MD 20892, 301–435–0810, lourdes.ponce@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: September 26, 2023.

Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

FR Doc. 2023–21590 Filed 9–29–23; 8:45 am

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITFs) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine or Oral Fluid (Mandatory Guidelines).

FOR FURTHER INFORMATION CONTACT: Anastasia Flanagan, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Rockville, Maryland 20857; 240–276–2600 (voice); Anastasia.Flanagan@samhsa.hhs.gov (email).

SUPPLEMENTARY INFORMATION: In accordance with Section 9.19 of the Mandatory Guidelines, a notice listing all currently HHS-certified laboratories and IITFs is published in the Federal Register during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the internet at https://www.samhsa.gov/workplace/resources/drug-testing/certified-lab-list.

The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITFs) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines) using Urine and of the laboratories currently certified to meet the standards of the Mandatory Guidelines using Oral Fluid.

The Mandatory Guidelines using Urine were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April 30, 2010 (75 FR 22809); and on January 23, 2017 (82 FR 7920).

The Mandatory Guidelines using Oral Fluid were first published in the Federal Register on October 25, 1999 (84 FR 57554) with an effective date of January 1, 2020.

The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71 and allowed urine drug testing only. The Mandatory Guidelines using Urine have since been revised, and new Mandatory Guidelines allowing for oral fluid drug testing have been published. The Mandatory Guidelines require strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on specimens for federal agencies. HHS does not allow IITFs to conduct oral fluid testing.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines using Urine and/or Oral Fluid. An HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that the test facility has met minimum standards. HHS does not allow IITFs to conduct oral fluid testing.

HHS-Certified Laboratories Approved To Conduct Oral Fluid Drug Testing

In accordance with the Mandatory Guidelines using Oral Fluid dated October 25, 2019 (84 FR 57554), the following HHS-certified laboratories meet the minimum standards to conduct drug and specimen validity tests on oral fluid specimens:

At this time, there are no laboratories certified to conduct drug and specimen validity tests on oral fluid specimens.

HHS-Certified Instrumented Initial Testing Facilities Approved To Conduct Urine Drug Testing

In accordance with the Mandatory Guidelines using Urine dated January 23, 2017 (82 FR 7920), the following HHS-certified IITFs meet the minimum
standards to conduct drug and specimen validity tests on urine specimens:  
Dynacare, 6628 50th Street NW,  
Edmonton, AB T6B 2N7,  
780–784–1190 (Formerly: Gamma- 
Dynacare Medical Laboratories)  
HHS-Certified Laboratories Approved 
To Conduct Urine Drug Testing  
In accordance with the Mandatory 
Guidelines using Urine dated January 
23, 2017 (82 FR 7920), the following 
HHS-certified laboratories meet the 
minimum standards to conduct drug 
and specimen validity tests on urine 
specimens:  
Alere Toxicology Services, 1111 Newton 
St., Gretna, LA 70053, 504–361– 
8989/800–433–8233 (Formerly:  
Kroll Laboratory Specialists, Inc., 
Laboratory Specialists, Inc.)  
Alere Toxicology Services, 450 
Southlake Blvd., Richmond, VA 
23236, 804–378–9130 (Formerly:  
Kroll Laboratory Specialists, Inc., 
Scientific Testing Laboratories, Inc.;  
Kroll Scientific Testing 
Laboratories, Inc.)  
Clinical Reference Laboratory, Inc., 8433 
Quivira Road, Lenexa, KS 66215– 
2802, 800–445–6917  
Desert Tox, LLC, 5425 E Bell Rd, Suite 
125, Scottsdale, AZ 85254, 602– 
457–5411/623–748–5045  
DrugScan, Inc., 200 Precision Road, 
Suite 200, Horsham, PA 19044, 
800–235–4890  
Dynacare *, 245 Pall Mall Street, 
London, ONT, Canada N6A 1P4, 
519–679–1630 (Formerly: Gamma- 
Dynacare Medical Laboratories)  
ElSohl Laboratories, Inc., 5 Industrial 
Park Drive, Oxford, MS 38655, 662– 
236–2609  
Laboratory Corporation of America 
Holdings, 7207 N. Gessner Road, 
Houston, TX 77040, 713–856–8288/ 
800–800–2387  
Laboratory Corporation of America 
Holdings, 69 First Ave., Raritan, NJ 
08869, 908–526–2400/800–437– 
4986 (Formerly: Roche Biomedical 
Laboratories, Inc.)  
Laboratory Corporation of America 
Holdings, 1120 Main Street, 
Southaven, MS 38671, 866–827– 
8042/800–233–6339 (Formerly: 
LabCorp Occupational Testing 
Services, Inc.; MedExpress/National 
Laboratory Center)  
LabOne, Inc. d/b/a Quest Diagnostics, 
10101 Renner Blvd., Lenexa, KS 
66219, 913–888–3927/800–873– 
8845 (Formerly: Quest Diagnostics 
Incorporated; LabOne, Inc.; Center 
for Laboratory Services, a Division 
of LabOne, Inc.)  
Legacy Laboratory Services Toxicology, 
1225 NE 2nd Ave., Portland, OR 
97232, 503–413–5295/800–950– 
5205  
MedTox Laboratories, Inc., 402 W. 
County Road D, St. Paul, MN 55112, 
651–636–7466/800–832–3244  
Minneapolis Veterans Affairs Medical 
Center, Forensic Toxicology 
Laboratory, 1 Veterans Drive, 
Minneapolis, MN 55417, 612–725– 
2088. Testing for Veterans Affairs 
(VA) Employees Only  
Pacific Toxicology Laboratories, 9348 
DeSoto Ave., Chatsworth, CA 
91311, 800–328–6942 (Formerly: 
Continenta Hospital Airport 
Toxicology Laboratory)  
Phamatech, Inc., 15175 Innovation 
Drive, San Diego, CA 92128, 888– 
635–5840  
Quest Diagnostics Incorporated, 400 
Egypt Rd. Norristown, PA 19403, 
610–631–4600/877–642–2216  
(Formerly: SmithKline Beecham 
Clinical Laboratories; SmithKline 
Bio-Science Laboratories)  
US Army Forensic Toxicology Drug 
Testing Laboratory, 2490 Wilson 
St., Fort George G. Meade, MD 
20755–5235, 301–677–7085, 
Testing for Department of Defense 
(DoD) Employees Only  
* The Standards Council of Canada 
(SCC) voted to end its Laboratory 
Accreditation Program for Substance 
Abuse (LAPSA) effective May 12, 1998. 
Laboratories certified through that 
program were accredited to conduct 
forensic urine drug testing as required 
by U.S. Department of Transportation 
(DOT) regulations. As of that date, the 
certification of those accredited 
Canadian laboratories will continue 
der DOT authority. The responsibility 
for conducting quarterly performance 
testing plus periodic on-site inspections 
of those LAPSA-accredited laboratories 
was transferred to the U.S. HHS, with 
the HHS’ NLCP contractor continuing to 
have an active role in the performance 
testing and laboratory inspection 
processes. Other Canadian laboratories 
wishing to be considered for the NLCP 
may apply directly to the NLCP 
contractor just as U.S. laboratories do. 
Upon finding a Canadian laboratory to 
be qualified, HHS will recommend that

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID FEMA—2023—0002]

Changes in Flood Hazard Determinations


ACTION: Notice.

SUMMARY: New or modified Base [1-percent annual chance] Flood Elevations (BFEs), base flood depths, Special Flood Hazard Area (SFHA) boundaries or zone designations, and/or regulatory floodways (hereinafter referred to as flood hazard determinations) as shown on the indicated Letter of Map Revision (LOMR) for each of the communities listed in the table below are finalized. Each LOMR revises the Flood Insurance Rate Maps (FIRMs), and in some cases the Flood Insurance Study (FIS) reports, currently in effect for the listed communities.

DATES: Each LOMR was finalized as indicated in the table below.

ADDRESSES: Each LOMR is available for inspection at both the respective Community Map Repository address listed in the table below and online through the FEMA Map Service Center at https://msc.fema.gov.

FOR FURTHER INFORMATION CONTACT: Rick Sachibit, Chief, Engineering Services Branch, Federal Insurance and Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472, (202) 646–7650, or (email) rick.sachibit@fema.dhs.gov; or visit the FEMA Mapping and Insurance eXchange (FMIX) online at https://www.floodmaps.fema.gov/fmix/fmix_main.html.